Spyre Therapeutics, Inc. (SYRE) is advancing its lead monoclonal antibody drug SPY001 for the treatment of patients with irritable bowel disorder [IBD]. This is going to consist of two large market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback